Investigating the Neuroprotective Effect of Cop-1 (Copaxone) in Acute Primary Angle Closure
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a randomised controlled trial to assess the neuroprotective effect of Cop-1
(Copaxone) in patients with acute primary angle closure (APAC). The standardized management
of APAC will include medical therapy to reduce intraocular pressure (IOP), followed by laser
peripheral iridotomy. Cop-1 will be administered in addition to standard therapy as a
subcutaneous dose once within 24 hours of presentation, and then one week later (total 2
injections). The control group will have placebo in addition to standard regimen. Subjects in
the study will have visual field test performed with the Humphrey Visual Field Analyzer II,
retinal nerve fibre layer (RNFL) thickness measured with the Stratus optical coherence
tomography (OCT) and Optic nerve head evaluated with the Heidelberg retinal tomography (HRT).
At least 2 baseline visual field tests will also be performed in the first week. Subsequent
visits will be at week 4, 8, 12 and 16. The outcome criteria will be difference in visual
field, RNFL thickness, and optic nerve head structural changes.